{"id":"W4405906667","doi":"10.1182/bloodadvances.2024014865","title":"Advancing drug development in myelodysplastic syndromes","year":2024,"lang":"en","type":"review","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"Genentech; U.S. Food and Drug Administration; National Institutes of Health; Paracelsus Medizinische Privatuniversität; Cincinnati Children's Hospital Medical Center; Università degli Studi di Firenze; National Heart, Lung, and Blood Institute; Acceleron; Eli Lilly and Company; Universidad de Salamanca; Memorial Sloan-Kettering Cancer Center; University of Washington; Bristol-Myers Squibb; Cleveland Clinic; University of Miami; Pfizer; Northwestern University; Incyte; National Cancer Institute; Servier; Ohio State University; University of Pennsylvania; Alexion Pharmaceuticals; Massachusetts General Hospital; Sanofi; AstraZeneca; Celgene","keywords":"Myelodysplastic syndromes; Medicine; Decitabine; Drug development; Clinical trial; Oncology; Stem cell; Transplantation; Intensive care medicine; Hematopoietic stem cell transplantation; Food and drug administration; Drug; Internal medicine; Pharmacology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001109721,0.0006263825,0.001106045,0.002581641,0.0002356511,0.001098968,0.0006681799,0.0008352674,0.005220968],"category_scores_gemma":[0.001151945,0.0002115527,0.0005713088,0.002243193,0.0002960113,0.001108909,0.0007210919,0.001651704,0.002251449],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005105447,"about_ca_system_score_gemma":0.001365587,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007445411,"about_ca_topic_score_gemma":0.001535556,"domain_scores_codex":[0.9997341,0.00006302597,0.00003831208,0.00003459525,0.0001046212,0.00002542514],"domain_scores_gemma":[0.9994398,0.0002531254,0.00008376568,0.00001659083,0.0001659684,0.00004078779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000679615,0.00006145937,0.0001125558,0.02008879,0.0001146599,0.0001089741,0.00004802693,0.0003215734,0.001381976,0.004601732,0.0267628,0.9463295],"study_design_scores_gemma":[0.00003541171,0.0001165279,0.0003945664,0.006585131,0.0001544855,0.0004562964,0.00003927165,0.0001064869,0.0004177489,0.001737117,0.9899445,0.00001258276],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001716432,0.9976854,0.0001574512,0.0003737449,0.0002011555,0.00001256064,0.00003561232,0.00001330185,0.001349116],"genre_scores_gemma":[0.0008301106,0.997824,0.0002954008,0.0002854091,0.00009108974,0.00001170541,0.00004753888,0.000002226389,0.0006126231],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005220968,"threshold_uncertainty_score":0.01746589,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02886272746914764,"score_gpt":0.3608832563954044,"score_spread":0.3320205289262568,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}